Abstract 2344
Background
The Economist Intelligence Unit takes a strategic approach to understand the impact of policy on lung cancer. Recommendations from our research, sponsored by MSD, will assist countries to improve systemic responses because outcomes remain poor and costs remain high despite scientific progress.
Methods
Our research centres on 13 countries: Austria, Belgium, Finland, France, Germany, Greece, Netherlands, Norway, Poland, Romania, Spain, Sweden, and the UK. Our literature review drew evidence from internationally-recognised sources and falls into 5 domains operationalised by 17 indicators assessing performance across the entire patient journey. After consultation with European experts, we populated our scorecard comparing policy and practice, examining service delivery, systems, access, financing and governance. Examination of preliminary findings in country workshops with clinicians, patient organisations and other key stakeholders enabled us to obtain nuanced information providing a clearer grasp on care than obtained from desk research alone.
Results
While patches of good practice exist, no country scores highly across all of our measurements. All but one country has a national cancer control plan: 75% are over five years old and do not incorporate recent oncological innovations. Clinical guidelines lack details on accelerating suspected lung cancer patients for diagnosis, referral pathways to secondary/tertiary care, supportive/palliative care, shared decision-making and psychological support within a specified time. Cancer registries exist in each country, yet clinicians report that clinically-focused cancer registries could house important information. Only 5 countries reimburse all four commonly used biomarkers for lung cancer.
Conclusions
Room for improvement in lung cancer policy exists across all the countries and domains we have studied. Our workshops ensured we focus on the most important opportunities for improving the delivery of lung cancer care relevant for each country. Now, based on the recommendations coming out of the research and agreed upon by stakeholders, we are in the policy development phase of our work where our goal is to assist policymakers improve care for people living with lung cancer in Europe.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
MSD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract